LIPIFLOW

TearScience, a medical device company, pioneered technologies and leads innovation to vastly improve evaluation and treatment of meibomian gland dysfunction (MGD). A progressive, obstructive disease and root cause of dry eye, MGD is distinguished by loss of function and structure of tear oil glands. MGD affects approximately 86% of the 300 million dry eye sufferers worldwide and is highly prevalent in the general ophthalmic population. LipiView II and new LipiScan with Dynamic Meibomian Imaging™ (DMI) distinctively images meibomian gland structure. The Korb Meibomian Gland Evaluator™ assists physicians to reproducibly assess gland function. LipiFlow uses Vectored Thermal Pulse™ (VTP) technology to precisely direct treatment from the inner-lid and has received clearance by the US Food and Drug Administration for use in patients with MGD. Sponsored and unsponsored multicenter, randomized, controlled clinical studies of LipiFlow consistently show its safety and sustained effectiveness. For additional information on how TearScience improves evaluation of MGD, meibomian gland function, and symptoms for patients with MGD worldwide, visit www.TearScience.com.

Company’s Keywords:

healthcare, medical devices, medical, health care, medical device, optometric, ophthalmic solutions, assessment, treatment for meibomian gland dysfunction, dry eye